<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01333085</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000698330</org_study_id>
    <secondary_id>FRE-GERCOR-CAPRA</secondary_id>
    <secondary_id>FRE-GERCOR-O08-1</secondary_id>
    <secondary_id>EU-21109</secondary_id>
    <secondary_id>EUDRACT-2008-005702-39</secondary_id>
    <nct_id>NCT01333085</nct_id>
  </id_info>
  <brief_title>Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery</brief_title>
  <acronym>CAPRA</acronym>
  <official_title>Phase I/II Study of Induction Chemotherapy With Weekly RAD001, Carboplatin and Paclitaxel in Unresectable or Inoperable Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GERCOR - Multidisciplinary Oncology Cooperative Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GERCOR - Multidisciplinary Oncology Cooperative Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy,&#xD;
      such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of giving&#xD;
      everolimus together with carboplatin and paclitaxel in treating patients with locally&#xD;
      advanced head and neck cancer that cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine the maximum-tolerated dose of everolimus when combined with carboplatin and&#xD;
           paclitaxel in chemonaïve patients with unresectable or inoperable locally advanced head&#xD;
           and neck squamous cell carcinoma. (Phase I)&#xD;
&#xD;
        -  To determine the safety profile of weekly everolimus in combination with carboplatin and&#xD;
           paclitaxel in chemonaïve patients with unresectable or inoperable locally advanced head&#xD;
           and neck squamous cell carcinoma. (Phase I)&#xD;
&#xD;
        -  To determine the anti-tumor activity of this regimen, in terms of objective response&#xD;
           rate of the combination, according to the RECIST criteria in these patients. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To identify molecular markers of resistance to this regimen in these patients.&#xD;
&#xD;
        -  To assess objective response rate before and after completion of radiation therapy in&#xD;
           these patients. (Phase II)&#xD;
&#xD;
      OUTLINE: This is a multicenter, phase I dose-escalation study of everolimus followed by a&#xD;
      phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive paclitaxel IV over 1 hour, carboplatin IV over 1 hour, and&#xD;
           escalating doses of oral everolimus on days 1, 8, and 15. Treatment repeats every 21&#xD;
           days for 3 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive paclitaxel and carboplatin as in phase I and oral everolimus&#xD;
           (at a dose determined in the phase I portion of the study) on days 1, 8, and 15.&#xD;
           Treatment repeats every 21 days for 3 courses in the absence of disease progression or&#xD;
           unacceptable toxicity.&#xD;
&#xD;
      After the completion of combination therapy, patients may receive radiotherapy or surgery, at&#xD;
      the investigator's discretion.&#xD;
&#xD;
      Blood samples are collected for translational research and molecular markers analysis at&#xD;
      baseline and weeks 1, 4, and 9. Tissue samples are collected at baseline and periodically&#xD;
      during the study for biomarker and other laboratory analysis.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 14 days and periodically&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>weekly</time_frame>
    <description>to determine the maximum tolerated dose (MTD) and recommended dose of weekly RAD001 in combination with carboplatin and paclitaxel (phase I)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>9 weeks</time_frame>
    <description>To access the objective response rate of the combination RAD001-carboplatin-Paclitaxel according the the RECIST criteria, after 9 weekly cycles (phase II)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>RAD001-paclitaxel-carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD001: 20,30 or 50 mg PO 9 weekly cycles Paclitaxel: 60 mg/m²IV, in 1 hour, 9 weekly cycles Carboplatin AUC2 IV in 1 hour,9 weekly cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <arm_group_label>RAD001-paclitaxel-carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <arm_group_label>RAD001-paclitaxel-carboplatin</arm_group_label>
    <other_name>everolimus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <arm_group_label>RAD001-paclitaxel-carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx,&#xD;
             larynx, or hypopharynx&#xD;
&#xD;
               -  Locally advanced disease (T4 N0-N3 disease)&#xD;
&#xD;
               -  Unresectable disease OR resectable disease with surgery contra-indication&#xD;
&#xD;
               -  No stage I, II, III, or IVc disease&#xD;
&#xD;
          -  Measurable lesions defined as those accurately measured in ≥ 1 dimension (longest&#xD;
             diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with&#xD;
             spiral CT scan&#xD;
&#xD;
          -  No known brain metastases (cerebral CT scan is not required if no symptom is present)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Total bilirubin ≤ 1.25 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases ≤ 2.5 times ULN&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 5 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Glycemia ≤ 1.5 times ULN&#xD;
&#xD;
          -  Cholesterol level ≤ 7.30 mmol/L&#xD;
&#xD;
          -  Serum total protein normal&#xD;
&#xD;
          -  Oxygen saturation &gt; 88%&#xD;
&#xD;
          -  Able to swallow pills&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No preexisting neuropathy ≥ grade 2&#xD;
&#xD;
          -  No uncontrolled disease including any of the following:&#xD;
&#xD;
               -  Diabetes&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Symptomatic congestive heart or pulmonary failure&#xD;
&#xD;
               -  Renal or hepatic chronic disease&#xD;
&#xD;
               -  Severe infectious disease&#xD;
&#xD;
          -  No active hemorrhagic syndrome&#xD;
&#xD;
          -  No prior history of cancer within the past 5 years, except in situ cervical cancer and&#xD;
             basal cell skin carcinoma&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Registration in a national health care system (CMU included)&#xD;
&#xD;
          -  Not eligible for organ preservation program&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior therapy for this cancer&#xD;
&#xD;
          -  No prior chemotherapy unless received for treatment of another primary tumor&#xD;
             considered in remission&#xD;
&#xD;
          -  No prior investigational drug&#xD;
&#xD;
          -  More than 30 days since prior participation in another therapeutic trial&#xD;
&#xD;
          -  No prior or concurrent radiotherapy (except anterior radiotherapy) unless received for&#xD;
             treatment of another primary tumor considered in remission&#xD;
&#xD;
          -  No concurrent CYP3A4 strong inhibitors (e.g., azole antimycotics [itraconazole,&#xD;
             ketoconazole], HIV protease inhibitor [ritonavir], erythromycin, anti-epileptic drugs&#xD;
             [phenytoin, carbamazepine])&#xD;
&#xD;
          -  No concurrent anti-coagulant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandrine Faivre</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Beaujon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Privé Saint Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <study_first_submitted>April 8, 2011</study_first_submitted>
  <study_first_submitted_qc>April 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2011</study_first_posted>
  <last_update_submitted>February 9, 2016</last_update_submitted>
  <last_update_submitted_qc>February 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV squamous cell carcinoma of the hypopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the larynx</keyword>
  <keyword>stage IV verrucous carcinoma of the larynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the lip and oral cavity</keyword>
  <keyword>stage IV verrucous carcinoma of the oral cavity</keyword>
  <keyword>stage IV squamous cell carcinoma of the oropharynx</keyword>
  <keyword>tongue cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

